Subcutaneous · Amylin analog
Eloralintide
17 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
17
Active
11
Recruiting
9
Completed
6
Sites
678
Countries
24
Endpoints
153
Composite endpoints
5
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
7
Phase 2
5
Phase 3
5
Trials by status
Not yet recruiting
1
Recruiting
9
Active, not recruiting
1
Completed
6
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
41
Weight & body composition
39
Patient-reported / QoL
22
Cardiometabolic biomarkers
16
Glycemic / diabetes
14
Other clinical outcomes
11
Other (unclassified)
6
Renal / kidney
3
Heart failure
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
CmaxSafety/PK
17
AUC₀–∞Safety/PK
17
Body weight, % changeWeight
12
BMI, changeWeight
8
PGI, changePRO/QoL
6
Body weight, absolute change (kg)Weight
6
Waist circumference, changeWeight
5
Triglycerides, changeBiomarker
5
Systolic BP, changeBiomarker
5
hs-CRP, changeBiomarker
5
EQ-5D indexPRO/QoL
5
HbA1c, changeGlycemic
4
SF-36 totalPRO/QoL
4
eGFR, changeRenal
3
Serious AEs (any)Safety/PK
3
Fasting glucose, changeGlycemic
3
≥5% weight-loss respondersWeight
3
≥10% weight-loss respondersWeight
3
Treatment-emergent AEs (any)Safety/PK
3
Total fat massWeight
2
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
17 of 17